Thrombolex Inc.

THROMBOLEX® innovates mechanically channeled thrombolysis, disrupting and dissolving pulmonary embolism thrombus in a single on-the-table session.

09/10/2026

Piece by piece, our new look is taking shape.

It's a fresh identity, built to match the premium therapy behind it.

The full reveal is almost here.

09/09/2026

We recently wrapped our Summer Sales Meeting, bringing together team members from across the organization around one focus: expanding physician access to the THROMBOLEX® procedure for patients with pulmonary embolism, peripheral vascular embolism, and venous thrombus.

Thank you to everyone who helped make it happen.

09/08/2026

THROMBOLEX® is aligning our look more closely to the premium therapy it represents.

Later this week, expect a look at our new identity.

The full reveal is coming soon.

Follow us to keep up.

06/30/2026

Do more with less.

It is the standard we hold ourselves to - in the design of the BASHIR® Family of Endovascular Devices, in the clinical programs we invest in, and in the resources we make available to the interventional community.

From single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) to a portfolio built to address the full spectrum of A&VTE, every element of what Thrombolex offers is grounded in one conviction: that better outcomes, efficient delivery, and clinical confidence should be accessible to every clinician and every patient who needs them.

Thrombolex.com

06/26/2026

Pulmonary embolism and venous thrombus require targeted, reliable intervention, and the BASHIR® Family of Endovascular Devices is built to deliver both.

The BASHIR® Endovascular Device and BASHIR® S-B Endovascular Device are FDA cleared for the treatment of PE and venous thrombus, supporting single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) with integrated mechanical clot fragmentation and targeted thrombolytic delivery. The BASHIR® Plus Endovascular Device offers variable shaft infusion lengths to address venous thrombus with extensive clot burden in a broader range of anatomical presentations.

Thrombolex.com

06/23/2026

For PERT teams, procedural efficiency is not measured in minutes alone. It is measured in the consistency, safety, and clinical confidence delivered for every patient.

In clinical experience with on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device for intermediate-risk PE, the median procedure time was approximately 39 minutes, with no major bleeding events observed in the reported cohort and no requirement for post-procedure infusion. This kind of structured, reproducible outcome is what PERT programs need to build clinical confidence across their institutions.

Thrombolex.com

06/18/2026

In PE care, what happens after the procedure matters as much as what happens during it.

Single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device is designed to support targeted clot fragmentation and thrombolytic delivery in a structured, efficient intervention, without the need for post-procedure infusion. Clinical experience has demonstrated no major bleeding events in the reported cohort, supporting a pathway that reduces intensive care utilization and total length of hospital stay.

For institutions managing acute PE patients, that kind of post-procedure efficiency is not incidental. It is part of what makes a clinically proven solution worth choosing.

Thrombolex.com

06/15/2026

A strong PERT program depends on having reliable, consistent tools that fit the way your team works.

The BASHIR® Endovascular Device is a standalone technology that requires no capital equipment and integrates into existing lab workflows across a broad range of healthcare facilities. Designed to support single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML), it gives PERT teams a targeted, clinically proven solution that delivers procedural consistency and clinical confidence, without adding complexity to an already demanding care environment.

Thrombolex.com

06/12/2026

The BASHIR® Endovascular Device's expandable infusion basket is engineered for mechanical fragmentation along with uniform delivery of thrombolytics to the segmental branches of the pulmonary arteries, creating focused pharmacologic exposure precisely where clot burden is greatest. This integrated approach supports a controlled, structured intervention that maintains procedural consistency from the first step to the last.

It is not just about where the therapy goes. It is about how reliably it gets there.

Thrombolex.com

06/09/2026

Not all venous thrombus presents in the same way, and not all devices are built to address that variability.

The BASHIR® Plus Endovascular Device is designed for the treatment of venous thrombus with extensive clot burden, offering variable shaft infusion lengths - available in +10, +20, +30, and +40 configurations - to support mechanical fragmentation along with targeted uniform thrombolytic delivery across a range of anatomical presentations. The expandable infusion basket enables precise pharmaco-mechanical lysis without the need for capital equipment, making it straightforward to integrate into existing lab workflows.

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Want your practice to be the top-listed Clinic in New Britain?